SGMO
HealthcareSangamo Therapeutics, Inc.
$0.44
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Sangamo Therapeutics, Inc. is a healthcare company within the biotechnology industry, with a market capitalization of $148.06 million and 183 employees. The company's revenue over the trailing twelve months was $32.88 million. The company's financial health is marked by significant losses, with a net income of -$108,909,000 over the trailing twelve months and an EBITDA of -$104,683,000. The gross margin was -219.1%, while the operating margin was -6119.3%. Returns on equity and assets were also negative at -480.0% and -68.1%, respectively. The company's balance sheet shows a debt-to-equity ratio of 407.24 and a current ratio of 0.88. The company's valuation is characterized by a forward P/E ratio of -1.91, indicating potential concerns about the company's profitability. Revenue growth over the past year was -98.8%. The company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Visit website →Key Statistics
- Market Cap
- $148.06M
- P/E Ratio
- N/A
- 52-Week High
- $1.51
- 52-Week Low
- $0.38
- Avg Volume
- 6.11M
- Beta
- 1.30
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 183